Physician profile
Phyllis E Solomon
NPI 1306337332
$770.27
in general payments reported to CMS, 2019-2025
14 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $95.71 · 2023: $92.39 · 2024: $270 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469 · Entertainment: $13.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.69 |
| Entertainment | $13.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $124.93 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $124.80 | 2021 | |
| Lilly USA, LLC | $116.66 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $109.98 | 2024-2025 | |
| Novo Nordisk INC | $77.41 | 2021-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $60.98 | 2021-2022 | |
| Exact Sciences Corporation | $27.53 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $25.38 | 2023 | |
| Glaxosmithkline, LLC. | $20.54 | 2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.18 | 2024 | Jardiance, Synjardy |
| Supernus Pharmaceuticals, INC. | $16.85 | 2025 | Qelbree |
| Exeltis, USA INC. | $15.81 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.42 | 2024 | |
| Optos, INC. | $13.80 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.